434 related articles for article (PubMed ID: 9744497)
1. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
3. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
4. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
5. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
6. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
7. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
8. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
9. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia.
Grey MR; Burgess R; Fisher A; Yin JA
Leuk Res; 1999 Jan; 23(1):29-35. PubMed ID: 9933132
[TBL] [Abstract][Full Text] [Related]
10. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype.
Lopes EC; Garcia M; Benavides F; Shen J; Conti CJ; Alvarez E; Hajos SE
Leuk Res; 2003 May; 27(5):413-23. PubMed ID: 12620293
[TBL] [Abstract][Full Text] [Related]
12. Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein.
Azare J; Pankova-Kholmyansky I; Salnikow K; Cohen D; Flescher E
Oncol Res; 2001; 12(8):315-23. PubMed ID: 11589302
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Pallis M; Turzanski J; Higashi Y; Russell N
Leuk Lymphoma; 2002 Jun; 43(6):1221-8. PubMed ID: 12152989
[TBL] [Abstract][Full Text] [Related]
14. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
15. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein.
Smith CD; Myers CB; Zilfou JT; Smith SN; Lawrence DS
Oncol Res; 2000; 12(5):219-29. PubMed ID: 11417747
[TBL] [Abstract][Full Text] [Related]
16. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
17. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
Tiberghien F; Loor F
Anticancer Drugs; 1996 Jul; 7(5):568-78. PubMed ID: 8862725
[TBL] [Abstract][Full Text] [Related]
18. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
19. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
